Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide

(2016) Ralf S. Schmid et al.   NEURO-ONCOLOGY

Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models

(2015) Amanda E.D. Van Swearingen et al.   CANCER RESEARCH

Toward precision medicine in glioblastoma: the promise and the challenges

(2015) Michael D. Prados et al.   NEURO-ONCOLOGY

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

(2015) Timothy J. Stuhlmiller et al.   Cell Reports

Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models

(2015) Amanda E.D. Van Swearingen et al.   CANCER RESEARCH

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2

(2015) Takayuki Yoshida et al.   Oncotarget

Adaptive Reprogramming of the Breast Cancer Kinome

(2014) T J Stuhlmiller et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors

(2014) R. El Meskini et al.   Disease Models & Mechanisms

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

(2014) R. Dienstmann et al.   MOLECULAR CANCER THERAPEUTICS

Contemporary murine models in preclinical astrocytoma drug development

(2014) Robert S. McNeill et al.   NEURO-ONCOLOGY

Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma

(2013) Krishna P.L. Bhat et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

New cast for a new era: preclinical cancer drug development revisited

(2013) Grit S. Herter-Sprie et al.   JOURNAL OF CLINICAL INVESTIGATION

Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis

(2013) M. Vitucci et al.   NEURO-ONCOLOGY

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency

(2012) W. L. See et al.   CANCER RESEARCH

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance

(2012) W. C. Zamboni et al.   CLINICAL CANCER RESEARCH

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

(2012) P. J. Roberts et al.   CLINICAL CANCER RESEARCH

In vivo models of primary brain tumors: pitfalls and perspectives

(2012) P. C. Huszthy et al.   NEURO-ONCOLOGY

Glioblastoma: From Molecular Pathology to Targeted Treatment

(2011) Timothy F. Cloughesy et al.   Annual Review of Pathology-Mechanisms of Disease

Genetically engineered mouse models of diffuse gliomas

(2011) Ralf S. Schmid et al.   BRAIN RESEARCH BULLETIN

Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain

(2011) Lionel M.L. Chow et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

(2011) D. Koul et al.   CLINICAL CANCER RESEARCH

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

mTOR signaling in glioblastoma: lessons learned from bench to bedside

(2010) D. Akhavan et al.   NEURO-ONCOLOGY

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

(2010) Jun Sunayama et al.   STEM CELLS